Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
While Merck can appeal, Halozyme said it expects the order to hold
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Subscribe To Our Newsletter & Stay Updated